Ghent University Academic Bibliography

Your filters: cql: author="Van Bruwaene, Siska" or (type any "bookEditor issueEditor" and editor="Van Bruwaene, Siska")

Add to list
- Journal Article
- A1
- open access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3291-3302
Add to list
- Miscellaneous
- open access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3381-3381
Add to list
- Journal Article
- A1
- open access
Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

Valerie Fonteyne (UGent) , Charles Van Praet (UGent) , Piet Ost (UGent) , Siska Van Bruwaene, Nick Liefhooghe, Charlien Berghen, Gert De Meerleer, Ben Vanneste (UGent) , Caroline Verbaeys, Sofie Verbeke, et al.

(2023) EUROPEAN UROLOGY FOCUS. 9(2). p.317-324
Add to list
- Journal Article
- A1
- open access
AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Jan Vanwelkenhuyzen (UGent) , Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost (UGent) , et al.

(2023) EUROPEAN UROLOGY OPEN SCIENCE. 53. p.63-66
Add to list
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) : a multicentre, open-label, phase 2 trial

Matthew R Smith, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Olof Ståhl, et al.

(2022) LANCET ONCOLOGY. 23(3). p.362-373
Add to list
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy

Piet Dirix, Michiel Strijbos, Tom Van den Mooter, Nick Liefhooghe, Siska Van Bruwaene, Pieter Uvin, Christophe Ghysel, Dieter Ost, Peter Schatteman, Samuel Bral, et al.

(2020) FUTURE ONCOLOGY. 16(16). p.1083-1089

Academic Bibliography

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) : a multicentre, open-label, phase 2 trial

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy

Contents

Support

Contact